AbbVie Inc. Q3 FY2026 earnings call

• Financial Strength & Capital Return: The company raised full-year guidance and announced a 5.2% increase in the quarterly dividend to $1.82 per share, marking over 350% dividend growth since inception.
• Immunology Leadership: SkyRizi and Rinvoq continue to exceed expectations with double-digit growth despite competitive entry. Sub-Q induction for SkyRizi in Crohn's received FDA approval, expected to accelerate new patient share.
• Pipeline Advancements: Acquired Apogee Therapeutics to add dermatology assets like Zumilokibar (Phase III starting later this year). Juvemo approved for Parkinson’s, joining a portfolio expected to peak above $5 billion. Etensimig submitted for multiple myeloma with anticipated 2027 approval.
• Operational Efficiency: Adjusted gross margin stood at 85.1%, with adjusted operating margin at 48.7%. Free cash flow generation remains strong, supporting dividends and M&A capacity.
• Strategic Focus: Management emphasizes long-term growth into the 2030s through differentiated assets in core areas (immunology, neuroscience, oncology) and selective expansion into obesity.

The company reported total net revenues of $17.4 billion, reflecting robust operational growth of more than 10%. Key segment performances include: Immunology, which delivered nearly $9.2 billion in revenue (approx. 53% of total), driven by SkyRizi ($5.8 billion, +22.9%) and Rinvoq ($2.7 billion, +24.3%), while Humira declined to $683 million (-30.6%). Neuroscience generated nearly $3.4 billion (approx. 20% of total), up 19.5%, with Vrelar at $1.1 billion (+14.3%), Botox Therapeutic at $1.1 billion (+9.8%), Ubrelvi at $449 million (+26.9%), Qulipta at $398 million (+38%), and Vylev at $286 million. Oncology revenues were $1.7 billion (approx. 10% of total), up 0.9%, led by Van Clexta ($803 million, +10.7%) but offset by Imbruvica declines (-26.1%). Aesthetics sales were nearly $1.2 billion (approx. 7% of total), down 1.8%, with Botox Cosmetic up 4.1% to $669 million and Juvederm down 11.8% to $222 million.

• Full-Year 2026 EPS: Raised by $0.11 at the midpoint to a range of $13.95–$13.99.
• Full-Year 2026 Revenue: Increased by $200 million to approximately $67.8 billion.
• Fourth Quarter 2026 Revenue: Anticipated at approximately $18.4 billion.
• Fourth Quarter 2026 EPS: Forecast between $3.83 and $3.87.
• Product Specifics: Immunology global sales outlook raised to $34.9 billion; Neuroscience to $13 billion; Oncology to $6.6 billion; Aesthetics unchanged at $5 billion.

• Biosimilar Competition: Continued erosion of Humira sales due to biosimilar competition.
• Payer Dynamics: Potential rebate concessions in immunology, though management expects low single-digit impacts.
• Regulatory Uncertainty: Ongoing litigation regarding IRA pricing eligibility for Botox; CMC-related Complete Response Letter for Bowie awaiting resubmission.
• Market Access: Delays in Medicare coverage for Juvemo impacting near-term ramp-up.
• Program Abuse: Challenges related to 340B program abuse affecting industry investment.

Q: Analyst asked about key dynamics for 2027 modeling and payer access for Rinvoq. / A: CEO Rob Michael highlighted that SkyRizi and Rinvoq are delivering incredible growth despite competition, fueled by catalysts like sub-Q induction and new derm indications. CFO Scott Reents noted consistent payer access with low single-digit rebate concessions. Commercial Officer Jeff Stewart confirmed favorable access is expected for upcoming Rinvoq vitiligo and alopecia areata approvals, maintaining the current pattern of strong physician demand driving access.

Q: Analyst sought details on SkyRizi sub-Q induction market share dynamics and the role of Alpha-4-Beta-7 combos. / A: R&D Chief Roopal Thakkar explained that sub-Q data showed superior endoscopic response vs. IV, strengthening frontline positioning. She noted the combo strategy aims to modify disease via tissue restoration, potentially moving to earlier lines of therapy. Jeff Stewart added that access takes ~60 days, with rapid share acceleration expected in H1 2027 as gastroenterologists respond to high efficacy data.

Q: Analyst asked about confidence in Imraclidine underdosing issues and which pipeline assets are underappreciated. / A: Roopal Thakkar stated higher doses (150mg) improve PK predictability and receptor occupancy, reducing variability. She identified Intentamig (myeloma) and TMAP-A as multibillion-dollar opportunities significantly under-called in street models. CEO Rob Michael added that the neuroscience franchise (psychiatry, migraine, Parkinson's) represents three $5B+ franchises not fully reflected in consensus, alongside upside from Zumilokibar.

Q: Analyst questioned the strategic rationale for participating in the 340B pilot and timelines for Bowie resubmission. / A: CEO Rob Michael explained participation aims to drive transparency and curb program abuse, protecting R&D investment, though financial impact is unclear. R&D Chief Roopal Thakkar clarified Bowie’s CRL was due to CMC issues, not safety/efficacy. Resubmission is targeted for year-end 2026, with a US decision expected mid-2027, following existing approvals in Europe and Canada.

Q: Analyst inquired about accelerating Phase III for ABBV-466 and competitiveness of Epkinley in frontline DLBCL. / A: Roopal Thakkar indicated interim data analysis could allow dropping lower-performing arms or pivoting to standard doses, potentially starting Phase III by late 2027. For Epkinley, Jeff Stewart emphasized the simplicity of adding one novel agent to familiar RCHOP regimens globally, expecting rapid adoption despite competitor readouts, noting partnership economics differ from direct sales.